Analysis – Page 382 – Goldea Capital

Harvard Bioscience Announces First Quarter 2026 Financial Results

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operations Progressing on Schedule Reaffirms Full Year 2026 Financial GuidanceHOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the first quarter ended March 31, 2026. “First quarter revenues were in line with our expectations and gross margin expanded year-over-year, while we remained profitable on an adjusted EBITDA basis,” said John Duke, President and Chief Executive Officer. “We are encouraged by the adoption rates of our NPI portfolio – specifically the MeshMEA™ organoid platform, and our BTX® Electroporation and SoHo™ Telemetry systems – which are deepening our reach into the biopharma sector. This...

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027 Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities Conference call today at 8:30 AM ET MIAMI, May 12, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced financial results for the first quarter...

Cal-Maine Foods and Sara Lee Frozen Bakery Announce Cal-Maine Foods’ Acquisition of Van’s Foods Brand, Advancing Cal-Maine Foods’ Diversification Strategy and Expanding Consumer-Facing Retail Presence

Written by Customer Service on May 12, 2026. Posted in Mergers And Acquisitions.

RIDGELAND, Miss, May 12, 2026 (GLOBE NEWSWIRE) — Cal-Maine Foods, Inc. (NASDAQ: CALM), the largest egg company in the United States and a leading player in the egg-based food industry, and Sara Lee Frozen Bakery, LLC, a leading manufacturer of premium frozen baked goods, today announced Cal-Maine Foods’ acquisition of certain assets of the Van’s Foods business of Sara Lee Frozen Bakery, LLC, a Kohlberg portfolio company. Van’s holds the top position in gluten-free waffles, establishing itself as a category leader within the fast-growing better-for-you frozen breakfast segment. This acquisition is aimed at supporting Cal-Maine Foods’ strategy to diversify its business model, grow in prepared foods business-to-consumer (B2C) retail, and deliver greater value across the supply chain. The addition of Van’s is expected to increase Cal-Maine...

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Lead clinical candidate IND filing in Acumen’s EBDTM (enhanced brain delivery) program targeted for mid-2027 Cash, cash equivalents and marketable securities of $128.4 million as of Mar. 31, 2026, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for...

George Weston Limited Reports First Quarter 2026 Results

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

TORONTO, May 12, 2026 (GLOBE NEWSWIRE) — George Weston Limited (TSX: WN) (“GWL” or the “Company”) today announced its consolidated unaudited results for the 12 weeks ended March 28, 2026(2). GWL’s 2026 First Quarter Report has been filed on SEDAR+ and is available at www.sedarplus.ca and in the Investor Centre section of the Company’s website at www.weston.ca. “George Weston delivered another quarter of strong financial results, reflecting consistent performance across our market leading businesses,” said Galen G. Weston, Chairman and Chief Executive Officer, George Weston Limited. “We are delighted to support Choice Properties with their transformational acquisition of First Capital assets, a deal that is completely in line with George Weston’s long term growth objectives.” Loblaw Companies Limited (“Loblaw”) delivered a...

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab Additional Phase 1b Trial Evaluating Cemsidomide in Combination with Approved Multiple Myeloma Therapies Expected to Initiate in the First Half of 2027 Expanded Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader Antibody Conjugates Cash, Cash Equivalents and Marketable Securities of $268.3 Million as of March 31, 2026 with Cash Runway to the End of 2028 WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD)...

eToro Reports First Quarter 2026 Results

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Net Contribution of $258 million, up 19% YoY Net Income of $82 Million, up 37% YoY Adjusted EBITDA of $109 million, up 35% YoY 4.02 million funded accounts, up 12% YoY NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) — eToro Group Ltd. (“eToro”, or the “Company”) (NASDAQ: ETOR), the trading and investing platform, today announced financial results for the first quarter ended March 31, 2026. “I’m incredibly proud of the eToro team for delivering our strongest quarterly financial results as a public company, while continuing to accelerate product innovation. In the first quarter, we introduced 24/7 trading for commodities, equities and indices, added Japanese equities, and launched crypto trading in New York. We also saw acceleration in product launches with many new apps within the eToro App Store, AI-powered Agent Portfolios, and an...

Olema Oncology Reports First Quarter 2026 Financial and Operating Results

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Top-line data from the Phase 3 OPERA-01 trial anticipated this fall; Phase 3 OPERA-02 trial continues to enroll patients First clinical data from OP-3136 Phase 1 study to be presented at ASCO Ended the first quarter with $505.3 million in cash, cash equivalents, and marketable securitiesSAN FRANCISCO, May 12, 2026 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the first quarter ended March 31, 2026. “We continued to meaningfully advance our pipeline of novel therapies focused on transforming the metastatic breast cancer treatment paradigm during the first quarter, with top-line...

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ET Upcoming Data Readout for Cohort 1 of OPGx-BEST1 Gene Therapy Study Expected in September 2026 LCA5 Accepted to FDA’s Rare Disease Evidence Principles (RDEP) Program and Enrolling Pivotal Trial RDH12, MERTK and RHO Programs Expected to Advance to Clinical Testing in the Next 12 Months Cash Runway into 2029 Expected to Support Multiple Clinical Inflection Points, Potential Product Approvals and Opportunities for Priority Review Vouchers RESEARCH TRIANGLE PARK, N.C., May 12, 2026 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced...

Broadwind Announces First Quarter 2026 Results

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

CICERO, Illinois, May 12, 2026 (GLOBE NEWSWIRE) — Broadwind (Nasdaq: BWEN, or the “Company”), a diversified precision manufacturer of specialized components and solutions serving global markets, today announced results for the first quarter 2026. FIRST QUARTER 2026 RESULTS(As compared to the first quarter 2025)Total revenue of $34.1 million GAAP net loss of ($0.5) million, or ($0.02) per diluted share Non-GAAP Adjusted EBITDA of $2.2 million, or 6.5% of total revenue* Total orders of $37.4 million, +23% y/y Ratio of net debt to trailing twelve-month non-GAAP adjusted EBITDA of 1.7x as of March 31, 2026*For a reconciliation of GAAP to non-GAAP metrics, please see the appendix of this release MANAGEMENT COMMENTARY “During the first quarter, we continued to advance our business transformation strategy, while delivering strong...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals